Sugi Predict

Sugi Predict / Compounds / SCHEMBL20541955

SCHEMBL20541955

SCHEMBL20541955

CC(C)n1cnc2c(NCCn3c(=O)[nH]c4ccccc43)nc(Cl)nc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 6/20 0.58
▸ CDK5 Q00535 12/20 0.48
▸ CDK2 P24941 12/20 0.48
▸ CDK5R1 Q15078 10/20 0.48
▸ CCNA2 P20248 9/20 0.48
▸ CCNA1 P78396 9/20 0.48
▸ DYRK1A Q13627 9/20 0.48
▸ NPC1 O15118 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ CSNK1D P48730 1/20 0.43
▸ CLK2 P49760 1/20 0.43
▸ HIPK4 Q8NE63 1/20 0.43
▸ SRPK1 Q96SB4 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3499988 0.83 CDK1 (0.44) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL30315450 0.83 CDK1 (0.44) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL20558099 0.81 CDK1 (0.42) CDK1CDK5CDK2CDK5R1DYRK1A
SCHEMBL20541790 0.78 CDK1 (0.61) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL17628610 0.77 CDK1 (0.79) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL1400442 0.74 CDK1 (1.00) CDK1CDK5CDK2DYRK1ANPC1
SCHEMBL20541883 0.74 CDK1 (0.59) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL30579416 0.74 CDK1 (0.59) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL15243326 0.74 CDK1 (0.67) CDK1CDK5CDK2CDK5R1CCNA2
SCHEMBL6817833 0.72 CDK1 (0.63) CDK1CDK5CDK2CDK5R1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK1 2497/4885CDK5 1931/4885CDK2 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback